Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer ' s Disease

Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm® (aducanumab-avwa)-treated patients at 6 months Donanemab reduced brain amyloid plaque levels vs. baseline by...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials